Adjuncts to levodopa therapy: Dopamine agonists

Neurology

Volumn 50, Issue 6 SUPPL.6, 1998, Pages

  Poewe, Werner ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; RECEPTOR SUBTYPE; ROPINIROLE; SEROTONIN RECEPTOR;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DYSKINESIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RECTAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0031840699     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.50.6_suppl_6.s23     Document Type: Review

References (48)

1. Birkmayer W, Hornykiewicz O. Der L-3,4-dioxyphenylalanin (=DOPA) Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 1961;73:787-788.
2. Cotzias CG, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
3. Lees AJ. Levodopa: the gold standard in the management of Parkinson's disease. In: Poewe W, Lees AJ, eds. Twenty years of Madopar: new avenues. Basel: Editiones Roche, 1994: 55-64.
4. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349.
5. Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986; 36:1528-1530.
6. Marsden CD. Late levodopa failure: pathophysiology and management. In: Poewe W, Lees AJ, eds. Twenty years of Madopar: new avenues. Basel: Editiones Roche, 1994:65-76.
7. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer 344 rats. Neurobiol Aging 1992;13:339-351.
8. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.
9. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radical in vitro. Brain Res 1994;657:207-213.
10. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951;76:251-253.
11. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neurol 1989;26:232-238.
12. Schachter M, Bedard P, Debona AG, et al. The role of D-1 and D-2 receptors. Nature 1980;286:157-159.
13. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 1991;114:601-617.
14. Lees AJ, Stern GM. Pergolide and lisuride for levodopa-induced oscillations. Lancet 1981;2:577.
15. Geminiani G, Fetoni V, Genitrini S, Giovannini P, Tamma F, Caraceni T. Cabergoline in Parkinson's disease complicated by motor fluctuations. Mov Disord 1996;11:495-500.
16. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK&F101468-A), a novel dopamine D2 agonist. Pharmacol Biochem Behav 1991;38:147-154.
17. Schrag AE, Brooks D, Brunt E, et al. The safety of ropinirole, a selective non-ergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol [in press].
18. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. Mov Disord [in press].
19. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
20. Calne DB, Teychenne PF, Claveria LE, et al. Bromocriptine in parkinsonism. BMJ 1974;4:442-444.
21. Lieberman AN, Neophytides A, Leibowitz M, et al. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 1983;37:95-108.
22. Lees AJ, Haddad S, Shaw KM. Bromocriptine in parkinsonism: a long-term study. Arch Neurol 1978;35:503-505.
23. UK Bromocriptine Research Group. Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. J Neurol Neurosurg Psychiatry 1989;52:77-82.
24. Larsen TA, Newman RP, LeWitt PA, Calne DB. Severity of Parkinson's disease and the dosage of bromocriptine. Neurology 1984;34:795-797.
25. Ahlskog JE, Muenter MD. Treatment of Parkinson's disease with pergolide: a double-blind study. Mayo Clin Proc 1988;63: 969-978.
26. Olanow CW. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;1:40-47.
27. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994;4:431-436.
28. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47: 785-788.
29. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1:403-406.
30. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:96-101.
31. Poewe W, Kleedorfer B, Wagner M, et al. Side effects of subcutaneous apomorphine in Parkinson's disease. Lancet 1989; 1:1084-1085.
32. Pollak P, Champay AS, Gaio JM, et al. Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease. Rev Neurol (Paris) 1990;146:116-122.
33. Montrastuc JL, Rascol O, Senard JM, et al. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin Neuropharmacol 1991;14:432-437.
34. Kleedorfer B, Turjanski N, Ryan R, et al. Intranasal apomorphine in Parkinson's disease. Neurology 1991;41:761-762.
35. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170.
36. Poewe W, Kleedorfer B, Wagner M, et al. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: long-term follow-up in 18 patients. Adv Neurol 1993;60: 656-659.
37. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
38. Rascol A, Montrastuc JL, Guirard-Chaumeil B, Clanet M. Bromocriptine as first treatment of Parkinson's disease: long-term results. Rev Neurol 1982;138:402-408.
39. Schwarz J, Scheidmann K, Trenkwalder C. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa. Eur Neurol 1997;37:236-238.
40. Bédard PJ, Gomez-Mancilla B, Blanchet P, et al. Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain. Kent: Wells Medical, 1997:101-113.
41. Baronti F, Mouradian M, Davis LT. Continuous s.c. infusions of lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781.
42. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking-day apomorphine in the long-term treatment of levodopa-induced interdose dyskinesias in Parkinson's disease. Mov Disord [in press].
43. de Saint Victor JF. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine. Mov Disord 1992;7: 283-287.
44. Poewe W, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988; 23:73-78.
45. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
46. Factor SA, Weiner WJ. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 1993;8:267-272.
47. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 1993;43:21-27.
48. Montrastuc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a three-year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.